Get the Stockscreener App
3.9869
0.25%
-0.0031
Humacyte Inc stock is currently priced at $3.9869, with a 24-hour trading volume of 683.88K.
It has seen a -0.25% decreased in the last 24 hours and a +27.97% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.95 pivot point. If it approaches the $4.05 resistance level, significant changes may occur.
Previous Close:
$3.99
Open:
$4.06
24h Volume:
683.88K
Market Cap:
$475.14M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-4.5826
EPS:
-0.87
Net Cash Flow:
$-75.59M
1W Performance:
+7.57%
1M Performance:
+27.97%
6M Performance:
+98.01%
1Y Performance:
+22.84%
1D Range:
$3.93
$4.21
52W Range:
$1.96
$5.60
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919 313 9633
Address
2525 E. NC Highway 54, Durham
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024
GlobeNewswire Inc.
Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update
GlobeNewswire Inc.
Investor Optimism Improves Slightly; Dow Jumps Over 250 Points
Benzinga
Should You Buy Humacyte (HUMA) Ahead of Earnings?
Zacks Investment Research
Humacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024
GlobeNewswire Inc.
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
Humacyte Inc Stock (HUMA) Financials Data
Humacyte Inc (HUMA) Net Income 2024
HUMA net income (TTM) was -$110.78 million for the quarter ending December 31, 2023, a -825.83% decrease year-over-year.
Humacyte Inc (HUMA) Cash Flow 2024
HUMA recorded a free cash flow (TTM) of -$75.58 million for the quarter ending December 31, 2023, a -4.72% decrease year-over-year.
Humacyte Inc (HUMA) Earnings per Share 2024
HUMA earnings per share (TTM) was -$1.07 for the quarter ending December 31, 2023, a -723.08% decline year-over-year.
About Humacyte Inc
Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded in 2004 and is based in Durham, North Carolina.
1.13%
Cap:
|
Volume (24h):